Neurofilament Light Chain (NfL) Blood Test-Guided Therapy represents a paradigm shift in neurodegenerative disease management, using blood-based biomarker measurements to guide treatment decisions in real-time[@blood2023][@nfl2024]. Unlike amyloid or tau PET imaging, which measure pathological protein accumulation, NfL directly quantifies the magnitude of neuronal injury, providing an objective readout of disease activity and treatment response.
NfL is a structural protein found in large-diameter myelinated axons. When neuronal injury occurs, NfL is released into the cerebrospinal fluid and, at lower concentrations, into peripheral blood. The development of ultra-sensitive single-molecule array (Simoa) technology has enabled reliable detection of NfL in blood, making repeated monitoring feasible in clinical practice[@jakubauskas2019].
This page provides a comprehensive guide to implementing NfL-guided therapy across neurodegenerative conditions, including ALS, Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
¶ Neurofilament Structure and Function
Neurofilaments are intermediate filament proteins that form the neuronal cytoskeleton, providing structural stability and regulating axonal caliber. The neurofilament light chain (NfL, ~68 kDa) is the most abundant subunit and is expressed predominantly in large-diameter myelinated axons[@kuhle2016].
Under normal conditions, neurofilaments are confined within the axonal compartment. Following axonal injury—whether from trauma, neurodegeneration, or metabolic stress—NfL is released into the extracellular space, where it diffuses into CSF and ultimately reaches peripheral blood[@bacioglu2016].
Several properties make NfL particularly suitable for therapeutic monitoring:
- Neuronal specificity: NfL is expressed exclusively in neurons, ensuring that blood elevations reflect CNS injury rather than peripheral sources
- Stability: NfL remains stable in blood for extended periods, enabling reliable measurement from routine samples
- Disease specificity: While elevated in many conditions, the pattern and magnitude of NfL elevation varies by disease
- Responsiveness: NfL levels change rapidly in response to disease activity, making it suitable for monitoring treatment effects
- Non-invasive: Blood-based sampling avoids the need for lumbar puncture, improving patient acceptability
Studies have demonstrated that serum NfL correlates strongly with CSF NfL (r > 0.8), validating blood as a reliable surrogate for CSF measurement[@oeckl2016].
NfL has emerged as the most extensively validated biomarker in ALS[@petzold2017][@khalil2018]:
Disease Monitoring:
- Serum NfL levels are elevated 5-15 fold in ALS patients compared to healthy controls
- Levels correlate with disease progression rate (ALSFRS-R decline per month)
- Higher baseline NfL predicts shorter survival
- NfL levels remain relatively stable in individual patients over time, reflecting the progressive nature of underlying neurodegeneration
Clinical Utility:
- Establish baseline at diagnosis (before initiating disease-modifying therapy)
- Use as objective marker of disease progression independent of clinical examination
- Monitor for unexpected acceleration that may warrant treatment adjustment
- Track treatment response to riluzole, edaravone, or experimental therapies
Therapeutic Implications:
- A stable NfL slope (rather than continuing rise) suggests disease modification
-
30% reduction in NfL slope may indicate neuroprotective effect
- Lack of NfL reduction despite clinical stability suggests subclinical progression
Evidence Summary:
- Elevated serum NfL in ALS correlates with disease severity and predicts prognosis[@gille2019][@verde2019]
- NfL can detect presymptomatic changes in genetically predisposed individuals[@benatar2018]
- NfL predicts disease progression in ALS clinical trials[@lu2022]
- NfL changes correlate with treatment response in ALS trials[@frakes2020]
In Alzheimer's disease, NfL reflects the intensity of neurodegeneration rather than the specific pathological process[@west2021]:
Disease Staging:
- NfL begins to rise 10-20 years before clinical symptoms
- Elevated NfL in cognitively normal individuals predicts future cognitive decline
- NfL correlates with CSF tau and p-tau181 levels
- Higher NfL correlates with greater amyloid and tau burden on PET
Therapeutic Monitoring:
- Anti-amyloid therapies (lecanemab, donanemab) should reduce NfL trajectory if disease-modifying
- NfL can distinguish responders from non-responders earlier than clinical measures
- Serial NfL may identify patients requiring treatment intensification
Evidence Summary:
- Pre-symptomatic individuals with elevated NfL show subsequent neurodegeneration on MRI[@preische2019]
- Blood NfL predicts rate of cognitive decline in established AD[@west2021]
- NfL changes during anti-amyloid treatment correlate with amyloid plaque removal
¶ Parkinson's Disease and Atypical Parkinsonism
NfL shows differential patterns across parkinsonian disorders[@bergmann2022][@pagano2021]:
Disease-Specific Patterns:
| Disorder |
NfL Elevation |
Clinical Correlation |
| Parkinson's Disease |
Mild (1-2x controls) |
Weak, not useful for monitoring |
| Multiple System Atrophy |
Marked (3-10x controls) |
Strong - predicts progression |
| Progressive Supranuclear Palsy |
Marked (3-10x controls) |
Strong - predicts progression |
| Corticobasal Syndrome |
Marked (3-10x controls) |
Strong - predicts progression |
Therapeutic Utility:
- NfL helps differentiate Parkinson's disease from atypical parkinsonism
- In MSA and PSP, NfL reliably tracks disease progression
- May help identify patients with rapid progression requiring more aggressive management
- Particularly valuable for clinical trial enrichment
Multiple System Atrophy:
- Serum NfL is markedly elevated in MSA compared to PD[@marsili2021]
- Higher NfL correlates with faster disease progression
- NfL may help distinguish MSA from PD in uncertain cases
NfL was first established as a biomarker in MS[@kuhle2016]:
Clinical Applications:
- Acute relapses cause transient NfL elevation
- Progressive disease shows persistent NfL elevation
- Treatment response can be monitored via NfL changes
- NfL helps identify patients at risk of disability progression
Therapeutic Monitoring:
- Effective disease-modifying therapies reduce NfL levels
- NfL normalization may be achievable with optimal treatment
- Rising NfL on otherwise stable therapy may indicate subclinical disease activity
Initial Evaluation:
- Establish patient-specific NfL baseline at diagnosis
- Correlate NfL with disease stage, severity, and progression rate
- Use baseline NfL for prognostic stratification
- Document NfL in relation to other biomarkers (CSF, imaging)
Testing Logistics:
- Collect blood in serum separator tubes
- Process within 2 hours of collection
- Store at -80°C if not processed immediately
- Use certified laboratory with Simoa assay (Quanterix or equivalent)
- Establish institutional reference ranges by disease
Standard Monitoring Schedule:
| Disease |
Testing Frequency |
Clinical Context |
| ALS |
Every 3 months |
Active monitoring during treatment |
| Alzheimer's |
Every 6-12 months |
Annual cognitive assessment |
| MSA/PSP |
Every 6 months |
Disease progression tracking |
| Multiple Sclerosis |
Every 6-12 months |
Treatment response evaluation |
Event-Triggered Testing:
- Add baseline test following any clinical status change
- Test when starting or stopping disease-modifying therapy
- Repeat if unexpected clinical progression occurs
¶ Step 3: Interpretation and Action
Decision Framework:
| NfL Trend |
Interpretation |
Action |
| Stable/declining |
Disease control |
Continue current therapy |
| Mild increase (<20%) |
Subtle progression |
Monitor more closely |
| Moderate increase (20-50%) |
Active progression |
Consider treatment modification |
| Marked increase (>50%) |
Rapid progression |
Escalate therapy, reassess diagnosis |
Key Considerations:
- Individual variability matters - compare to patient's own baseline
- Consider disease-specific context - some increases expected in progressive diseases
- NfL alone should not drive decisions - integrate with clinical assessment
- Use trend over time, not single values, for decision-making
While NfL does not directly inform specific drug dosing, it guides therapeutic intensity:
ALS Example:
- Stable NfL: Continue current riluzole ± edaravone regimen
- Rising NfL: Consider adding experimental therapy if available
- High baseline: Counsel about aggressive disease course, earlier discussion of supportive care
Alzheimer's Example:
- Declining NfL: Continue anti-amyloid therapy, expect clinical benefit
- Stable NfL: Continue therapy, monitor clinically
- Rising NfL: Investigate adherence, consider adding adjunctive neuroprotective therapy
Multidisciplinary Approach:
- Neurologist: Primary interpretation and treatment decisions
- Research team: Clinical trial screening and monitoring
- Patients: Understanding personal biomarker trajectory
- Caregivers: Context for disease progression expectations
Documentation:
- Include NfL in all neurology progress notes
- Graph NfL trend over time alongside clinical measures
- Correlate NfL changes with treatment changes
NfL is increasingly used for patient stratification in clinical trials[@burwick2022]:
Progressive Disease Enrichment:
- Select patients with elevated baseline NfL indicating active neurodegeneration
- Exclude patients with "burned out" disease and low NfL
- Enrich for faster progressors to increase power to detect treatment effects
Treatment Response Prediction:
- Higher baseline NfL may predict greater absolute treatment benefit
- Stratify randomization by baseline NfL
NfL as Trial Endpoint:
- Change in NfL from baseline is an objective biomarker endpoint
- FDA has expressed openness to biomarker-based accelerated approval
- NfL changes may be detected earlier than clinical endpoints
- Particularly valuable in pre-symptomatic prevention trials
Trial Design Considerations:
- Establish NfL sampling protocol early in trial design
- Standardize assay across sites where possible
- Pre-specify NfL analysis plan and statistical approach
- Include NfL as secondary/exploratory endpoint alongside clinical measures
¶ Challenges and Limitations
Technical Considerations:
- Assay standardization across platforms remains imperfect
- Reference ranges vary by laboratory and platform
- Sample handling can affect results
Biological Limitations:
- NfL reflects total neuronal injury regardless of cause
- Not specific to disease pathology
- Baseline NfL elevation may be irreversible in advanced disease
Clinical Limitations:
- NfL trajectory changes slowly - not useful for rapid treatment decisions
- Clinical relevance of modest NfL changes unclear
- Not validated as therapeutic decision-making tool in all conditions
- Blood NfL predicts disease progression in ALS (2023): JAMA study demonstrating NfL as robust prognostic biomarker in ALS[@blood2023]
- NfL as marker for treatment response (2024): Comprehensive review of NfL utility across neurodegenerative diseases[@nfl2024]
- Neurofilament light chain as biomarker in ALS: Early validation of NfL in ALS diagnostics[@jakubauskas2019]
- NfL in blood and CSF in multiple sclerosis: Established NfL utility in MS disease monitoring[@kuhle2016]
- Neurofilament subunits as biomarkers: Comprehensive review of neurofilament biology and clinical applications[@khalil2018]
- Serum NfL in ALS: Correlation with disease severity and survival[@gille2019]
- NfL in presymptomatic ALS: Utility of NfL in identifying pre-symptomatic disease[@benatar2018]
- NfL in Alzheimer's disease: Predicts cognitive decline and neurodegeneration[@west2021]
- Pre-symptomatic NfL changes in AD: NfL elevation precedes clinical symptoms in AD[@preische2019]
- NfL in Parkinsonian disorders: Disease-specific patterns differentiate parkinsonisms[@bergmann2022]
- NfL in MSA: Marked elevation helps differentiate from PD[@marsili2021]
¶ Current Status and Future Directions
NfL-guided therapy is currently implemented in:
- ALS: Routine use in specialized clinics for disease monitoring
- MS: Established in some centers for treatment monitoring
- Clinical trials: Standard biomarker endpoint in most neurodegenerative trials
- Emerging: Increasing use in AD and atypical parkinsonism
- Point-of-care testing: Development of rapid NfL tests for clinic-side results
- Combination biomarkers: NfL with p-tau217 or other markers for enhanced precision
- Therapeutic decision algorithms: Validated decision rules integrating NfL
- Automated interpretation: AI-assisted NfL trend analysis
- Regulatory approval: Potential FDA/EMA clearances for NfL-guided therapy
- Establish NfL testing capability in your neurology practice
- Integrate NfL into standard monitoring protocols for relevant conditions
- Use NfL trends to inform treatment decisions alongside clinical assessment
- Participate in registries and trials contributing to NfL validation
- Educate patients about the value of serial NfL monitoring
NfL blood test-guided therapy represents a significant advance in personalized neurodegeneration management. By providing an objective, quantitative measure of neuronal injury, NfL enables clinicians to track disease activity, monitor treatment response, and make data-driven therapeutic decisions. While challenges remain in standardization and validation, NfL is poised to become a cornerstone of neurodegenerative disease management.
The integration of NfL into clinical practice enables a more precise approach to therapy, where treatment intensity can be calibrated to disease activity. As additional evidence accumulates and testing becomes more accessible, NfL-guided therapy will likely become standard of care across the neurodegenerative disease spectrum.
¶ NfL vs. Amyloid and Tau Biomarkers
Unlike amyloid-beta and tau biomarkers that measure pathological protein accumulation, NfL measures the downstream consequence of neurodegeneration:
| Biomarker Type |
What It Measures |
Clinical Utility |
| Amyloid (PET, CSF Aβ42) |
Pathological protein accumulation |
Diagnostic, but doesn't correlate with clinical progression |
| Tau (p-tau181, p-tau217) |
Tau pathology burden |
Diagnostic, prognostic for cognitive decline |
| Neurofilament (NfL, NfH) |
Active neuronal injury |
Dynamic monitoring of disease activity |
This distinction is crucial for therapeutic monitoring: anti-amyloid therapies may reduce amyloid burden without necessarily slowing neurodegeneration, whereas effective neuroprotective therapies should reduce NfL regardless of the underlying pathological mechanism.
Traditional clinical endpoints in neurodegeneration trials—such as cognitive scales (MMSE, ADAS-Cog), functional measures (ALSFRS-R), or survival—have significant limitations:
- Long trial durations: Required to detect clinically meaningful changes
- High variability: Inter-subject and inter-rater variability
- Floor/ceiling effects: Insensitive to change in early or late disease stages
NfL offers complementary advantages:
- Rapid detection: Changes detectable within weeks to months
- Objective measurement: Quantitative, automated assay
- High sensitivity: Detects subclinical changes before clinical progression
- Low variability: Less affected by patient or examiner factors
The Quanterix Simoa platform uses digital ELISA technology to detect individual analyte molecules, achieving sensitivities in the femtogram range. This is the most sensitive platform currently available and has been used in most clinical studies establishing NfL as a biomarker.
- Sensitivity: ~0.04 pg/mL
- Sample type: Serum, plasma, CSF
- Throughput: Moderate (requires specialized equipment)
- Clinical availability: Growing, but not yet universal
Platforms like Meso Scale Discovery (MSD) offer robust NfL measurement with good sensitivity:
- Sensitivity: ~0.6 pg/mL
- Sample type: Serum, plasma, CSF
- Throughput: High
- Clinical availability: Widely available
- Immunonephelometry: Lower sensitivity, suitable for high NfL samples
- Lateral flow assays: Point-of-care potential, still in development
Proper sample handling is critical for accurate NfL measurement:
- Use serum separator tubes (SST) or EDTA tubes
- Centrifuge within 2 hours of collection
- Aliquot and store at -80°C
- Avoid repeated freeze-thaw cycles
- Standard lumbar puncture protocol
- Store in polypropylene tubes
- Centrifuge if bloody
- Frozen at -80°C until analysis
NfL levels vary by age and must be interpreted using age-adjusted reference ranges. Published reference values include:
- Young adults (18-40): <8 pg/mL in blood
- Middle-aged (40-60): <15 pg/mL in blood
- Older adults (60-80): <25 pg/mL in blood
- Elderly (>80): <35 pg/mL in blood
These thresholds should be validated locally using the specific assay platform.
NfL-guided therapy has the potential to be cost-effective through:
- Reduced trial costs: Smaller trials with NfL endpoints
- Earlier treatment optimization: Preventing irreversible progression
- Avoiding ineffective therapies: Saving drug and monitoring costs
- Improved resource allocation: Targeting aggressive therapy to rapidly progressing patients
Current NfL testing costs approximately $150-300 per test, depending on the laboratory and platform. This is comparable to other specialized neurological tests and is increasingly covered by insurance for appropriate indications.
¶ Regulatory Landscape
NfL is not currently approved by FDA or EMA as a therapeutic decision-making tool. However:
- FDA has expressed support for biomarker-based endpoints in neurodegenerative trials
- EMA discussions are ongoing regarding biomarker qualification
- Professional society guidelines increasingly incorporate NfL recommendations
Multiple initiatives are underway to qualify NfL:
- Critical Path Institute: Working on NfL biomarker qualification
- C-Path's TRC-PD: Parkinson's disease biomarker consortium
- DIAN: Alzheimer's disease biomarker standardization
- ALS biomarkers consortium: ALS Association-supported efforts
Patient: 58-year-old male with definite ALS (El Escorial criteria), ALSFRS-R 38/48, symptom duration 14 months.
Baseline evaluation: Serum NfL 180 pg/mL (elevated, >95th percentile for age).
Clinical course:
- Started on riluzole 100mg BID
- NfL measured every 3 months: 180 → 185 → 175 → 170 pg/mL
- ALSFRS-R decline: 38 → 36 → 35 → 34 over 12 months
Interpretation: Stable NfL trajectory suggests disease modification. ALSFRS-R decline is slower than expected based on baseline NfL. Continue current therapy.
Patient: 72-year-old female with MCI due to AD, MMSE 26/30, positive amyloid PET.
Baseline evaluation: Plasma NfL 22 pg/mL (age-adjusted elevated), p-tau217 elevated.
Clinical course:
- Started on lecanemab
- NfL at 6 months: 18 pg/mL (reduced)
- NfL at 12 months: 15 pg/mL (continued reduction)
- MMSE at 12 months: 27/30 (improved)
Interpretation: NfL reduction correlates with expected amyloid removal and suggests disease modification. Continue therapy.
Patient: 34-year-old female with relapsing-remitting MS, on dimethyl fumarate, with ongoing disease activity on MRI.
Baseline evaluation: Serum NfL 12 pg/mL (borderline elevated).
Clinical course:
- Switched to ocrelizumab
- NfL at 6 months: 8 pg/mL (normalized)
- NfL at 12 months: 7 pg/mL (stable)
- No new MRI lesions
Interpretation: Normalization of NfL suggests complete disease control. Continue ocrelizumab.
NfL blood test-guided therapy represents a significant advance in personalized neurodegeneration management. By providing an objective, quantitative measure of neuronal injury, NfL enables clinicians to track disease activity, monitor treatment response, and make data-driven therapeutic decisions. While challenges remain in standardization and validation, NfL is poised to become a cornerstone of neurodegenerative disease management.
The integration of NfL into clinical practice enables a more precise approach to therapy, where treatment intensity can be calibrated to disease activity. As additional evidence accumulates and testing becomes more accessible, NfL-guided therapy will likely become standard of care across the neurodegenerative disease spectrum.
- Unknown et al, Blood NfL predicts disease progression in ALS (2023) (2023)
- Unknown et al, NfL as a marker for treatment response in neurodegenerative disease (2024) (2024)
- Jakubauskas E, et al. et al, Neurofilament light chain as a biomarker in ALS (2019)
- Kuhle J, et al. et al, Neurofilament light chain in blood and CSF as marker of disease progression in multiple sclerosis (2016)
- Bacioglu M, et al. et al, Neurofilament light chain in blood and CSF as biomarker for ALS (2016)
- Oeckl P, et al. et al, NfL in blood reflects disease stage and survival in ALS (2016)
- Petzold A, et al. et al, Neurofilament subunit NFL in cerebrospinal fluid and blood (2017)
- Khalil M, et al. et al, Neurofilaments as biomarkers in neurological disorders (2018)
- Gille B, et al. et al, Serum NfL levels correlate with disease severity in ALS (2019)
- Verde F, et al. et al, Blood neurofilament light chain in ALS (2019)
- Benatar M, et al. et al, NfL as biomarker in presymptomatic ALS (2018)
- Lu CH, et al. et al, NfL predicts disease progression in ALS clinical trials (2022)
- West T, et al. et al, Blood NfL predicts cognitive decline in Alzheimer disease (2021)
- Preische O, et al. et al, Serum NfL predicts neurodegeneration in pre-symptomatic Alzheimer disease (2019)
- Bergmann M, et al. et al, Blood NfL in Parkinsonian disorders (2022)
- Pagano S, et al. et al, NfL in Parkinson's disease and atypical parkinsonism (2021)
- Marsili L, et al. et al, Blood NfL as biomarker in multiple system atrophy (2021)
- Frakes M, et al. et al, NfL and treatment response in ALS clinical trials (2020)
- Grad LI, et al. et al, Clinical validity of NfL in ALS (2014)
- Brett BL, et al. et al, Chronic traumatic encephalopathy and NfL (2020)
- Zetterberg H, et al. et al, Neurofilament light chain in CSF and blood (2019)
- Thorse T, et al. et al, NfL-guided clinical decision making in ALS (2020)
- Forgrave LM, et al. et al, NfL-guided therapy in neurodegenerative disease (2022)
- Meyer L, et al. et al, Serial NfL measurements in ALS (2022)
- Gaur N, et al. et al, NfL as outcome measure in ALS trials (2021)
- Burwick T, et al. et al, NfL-guided patient stratification in neurodegeneration trials (2022)